2021
Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma
Meza L, Malhotra J, Favorito C, Pal S. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology 2021, 18: 21-33. PMID: 34766841, DOI: 10.2217/fon-2021-0570.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMetastatic renal cell carcinomaMetastatic urothelial carcinomaTargeted therapyTreatment of metastatic RCCMetastatic renal cellNonresponders to monotherapyRenal cell carcinomaIncrease clinical responsesImmunotherapy combinationsMetastatic RCCUrothelial carcinomaClinical responseCell carcinomaProgressive diseaseIO agentsTreatment optionsRenal cellsImmunotherapyQuality of lifeCabozantinibMonotherapyCarcinomaNovel approachesNonrespondersTherapy
2020
Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer.
Zengin Z, Salgia N, Chehrazi-Raffle A, Meza L, Malhotra J, Pal S. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. The Cancer Journal 2020, 26: 432-440. PMID: 32947311, DOI: 10.1097/ppo.0000000000000473.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsMetastatic renal cell carcinomaRenal cell carcinomaCheckpoint inhibitorsAdverse eventsCell carcinomaDeath ligand 1 (PD-L1) immune checkpoint inhibitorsAnti-programmed death-1/Common immune-related adverse eventsImmune-related adverse eventsPivotal phase III trialsPrevious treatment optionsPhase III trialsDeath-1/Advanced kidney cancerRecent therapeutic advancementsUnique toxicity profileDrug Administration approvalFrontline regimensIII trialsClinical outcomesTreatment optionsRare toxicityAdministration approvalTargeted therapy